Drug Device Combination Global Market Report 2024

The global drug device combination market has grown rapidly in recent years. It will grow from $120.37 billion in 2023 to $134.41 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth observed in the historical period can be attributed to factors such as increasing medical innovation, a rise in chronic diseases, the adoption of patient-centric approaches, advances in biologics, challenges associated with monotherapy, and evolving clinical needs in the healthcare sector.

The global drug device combination market is expected to see rapid growth in the next few years. It will grow to $205.86 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated growth in the forecast period can be attributed to factors such as patient empowerment and engagement, the ongoing digitalization of healthcare, global market expansion, the emergence of novel therapies, and the shift towards value-based healthcare models. Major trends in the forecast period encompass advancements in therapeutic approaches, the management of complex diseases, the promotion of patient-centric care, continuous technological innovations, and regulatory support for healthcare initiatives.

The drug-device combination market is witnessing substantial growth driven by the increasing prevalence of chronic diseases. Chronic diseases, persisting for a year or longer and requiring ongoing medical care, include conditions like heart disease and diabetes. Drug-device combinations, encompassing therapeutic and diagnostic products, play a pivotal role in effectively treating individuals with chronic diseases. As per the World Health Organization's report, the global incidence of diabetes surpassed 420 million in 2022, with projections indicating a rise to 578 million by 2030 and 700 million by 2045. This escalating prevalence underscores the critical role of drug-device combinations in managing chronic diseases, thereby propelling the growth of the market.

The drug-device combination market is expected to experience growth propelled by an increase in casualties resulting from accidents. Accidents, often unforeseen and leading to harm or injury, can be effectively managed and prevented through the use of drug-device combinations. These combinations facilitate targeted medical interventions, enhancing patient safety in the aftermath of accidents. In 2021, Canada reported 1,768 motor vehicle fatalities, indicating a 1.3% increase from the previous year. The role of drug-device combinations in managing casualties and providing critical medical interventions positions them as integral components in accident-related healthcare solutions, thereby contributing to the growth of the market.

Technological advancement emerges as a key trend shaping the drug-device combination market. Major corporations are introducing innovative technologies to fortify their market positions. A notable example is Owen Mumford's Aidaptus auto-injector platform, launched in September 2021. This two-stage, spring-powered auto-injector incorporates self-adjusting plunger stopper sensing technology, adapting to various stopper positions and filling levels in prefilled glass syringes. Such advancements enhance the precision and efficiency of drug delivery, showcasing the industry's commitment to leveraging technology for improved healthcare outcomes.

Major companies operating in the drug-device combination market are introducing distinctive products to streamline administration processes. An exemplary launch is the G-Lasta Subcutaneous Injection 3.6 mg BodyPod by Terumo Corporation and Kyowa Kirin. This drug-device combination involves an automated injection device attached during chemotherapy, administering G-Lasta to reduce febrile neutropenia incidence. The automated system eliminates the need for additional outpatient visits, alleviating the burden on patients and exemplifying how innovative drug-device combinations contribute to enhanced treatment protocols and patient care.

In July 2021, BD, a renowned US-based medical device company, successfully acquired Zebrasci for an undisclosed sum. This strategic acquisition is poised to enhance BD's contract development service capabilities, specifically in the areas of testing and validation of combination products. By integrating Zebrasci's expertise, BD aims to strengthen its market position in the field of medical devices. Zebrasci, the acquired company, is a prominent US-based biotechnology firm specializing in the development of combination products.

Major companies operating in the drug device combination market report are The 3M Company, Abbott India Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, C. R. Bard Inc., Medtronic PLC, Amgen Inc., Ypsomed Holding AG, Micron Biomedical Inc., MetP Pharma AG, Sonceboz SA, Propeller Health B.D. Inc., Lepu Medical Technology (Beijing) Co. Ltd., Eitan Medical Ltd., Vaxess Technologies Inc., Subcuject Aps, Allergan PLC, Terumo Corporation, Stryker Corporation, Becton Dickinson and Company, Novartis AG, Zimmer Biomet Holdings Inc., MediPrint Ophthalmics, Arrow International Inc., Alcon Inc., W. L. Gore & Associates Inc., Cook Medical LLC, Pinnacle Biologics Inc., GlaxoSmithKline PLC, and Mylan N.V.

North America was the largest region in the drug-device combination market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug device combination market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug device combination market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of drug-device combination products include auto-injectors, microneedle patches, digital pills, smart inhalers, drug delivery hydrogels, drug-eluting lenses, and other products. These products find applications in various medical fields such as orthopedic diseases, respiratory diseases, diabetes, oncology, cardiovascular diseases, among others. The end users of drug-device combination products include clinics, hospitals, home care settings, ambulatory care centers, and others. These products are distributed through direct tenders, retail sales, and other distribution channels.

This report provides drug-device combination market statistics, including drug-device combination industry global market size, regional shares, competitors with an drug-device combination market share, detailed drug-device combination market segments, market trends and opportunities, and any further data you may need to thrive in the drug-device combination industry. This drug-device combination market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug-device combination market consists of sales of catheter and advanced wound care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.